Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.80 EUR
Change Today +0.066 / 2.41%
Volume 0.0
As of 3:43 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

solazyme inc (S7Y) Snapshot

Open
€2.78
Previous Close
€2.74
Day High
€2.84
Day Low
€2.74
52 Week High
06/18/14 - €9.04
52 Week Low
02/26/15 - €1.49
Market Cap
224.3M
Average Volume 10 Days
155.0
EPS TTM
--
Shares Outstanding
80.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SOLAZYME INC (S7Y)

solazyme inc (S7Y) Related Businessweek News

View More BusinessWeek News

solazyme inc (S7Y) Details

Solazyme, Inc. manufactures and sells renewable oils and other bioproducts. Its proprietary technology transforms a range of plant-based sugars into triglyceride oils and other bioproducts. The company offers renewable tailored oils, such as oleic oils that provide sustainable solutions within the food, lubricant, functional fluid, and oleo chemical markets; and drop-in replacements and blendstocks for marine, motor vehicle, and jet fuels, as well as replacements for petrochemicals, oleochemicals, and functional fluids. It also provides fuels, including SoladieselBD and SoladieselRD for on-road applications; ultra-low sulfur diesel; and Solajet for aviation use. In addition, the company offers microalgae-based food ingredients consisting of Tailored oils and powdered oils; and powdered ingredients comprising AlgaVia whole algal flour, AlgaVia whole algal protein, AlgaVia lipid powder, and encapsulated oils. Additionally, it provides skin and personal care products under the Algenist brand name, which include concentrated reconstructing serum, an anti-aging serum; complete eye renewal balm; firming and lifting cream, an anti-aging moisturizing cream; advanced anti-aging repairing oil, a face oil formulation; and genius cream. The company was incorporated in 2003 and is headquartered in South San Francisco, California.

266 Employees
Last Reported Date: 03/6/15
Founded in 2003

solazyme inc (S7Y) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $560.0K
Chief Financial Officer and Chief Operating O...
Total Annual Compensation: $410.4K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $335.0K
Chief Technology Officer
Total Annual Compensation: $370.8K
Strategic Advisor
Total Annual Compensation: $378.8K
Compensation as of Fiscal Year 2014.

solazyme inc (S7Y) Key Developments

Solazyme, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015

Solazyme, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $12,605,000 compared with $12,391,000 in the first quarter of 2014. Loss from operations was $26,311,000 against $32,441,000 a year ago. Net loss was $34,665,000 or $0.44 per basic and diluted share against $34,681,000 or $0.50 per basic and diluted share a year ago. Net loss (non-GAAP) was $29,533,000 or $0.37 per basic and diluted share against $30,528,000 or $0.44 per basic and diluted share a year ago. Operating cash burn, including a $3 million increase in working capital, was $26.8 million for the first quarter. The company ended the quarter with a cash balance of $174 million. Corporate CapEx, including SB Oils JV equity investments, are expected to total between $20 million and $30 million in 2015 in line with previous guidance, and approximately 50% below last year. Excluding the JV revenues, the company maintains its outlook for reported revenue growth to be greater than 15% in 2015. Operating cash burn to be below $100 million as the company manage its costs, its production ramp and its investments.

Solazyme, Inc. to Report Q1, 2015 Results on May 06, 2015

Solazyme, Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on May 06, 2015

Solazyme, Inc., Q1 2015 Earnings Call, May 06, 2015

Solazyme, Inc., Q1 2015 Earnings Call, May 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
S7Y:GR €2.80 EUR +0.066

S7Y Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for S7Y.
View Industry Companies
 

Industry Analysis

S7Y

Industry Average

Valuation S7Y Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SOLAZYME INC, please visit www.solazyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.